KEY TAKEAWAYS
- The SCOUT-1 trial aimed to evaluate the effectiveness of standard treatment sequences and assess patient needs and QoL in the routine management of advanced OC.
- The result demonstrated that the cumulative data analysis aligns with existing epidemiological data.
Researchers aimed to evaluate the effectiveness of standard treatment sequences and assess patient needs and quality of life(QoL) in routine management of primary advanced ovarian cancer (OC).
Participating sites were requested for cumulative data submission on OC patients they have treated. The study also gathered information on site characteristics, including type and certification.
The data analysis used descriptive and exploratory statistical methods for a comprehensive examination of the collected information.
Of the 73 sites initiated, characteristics were provided by 55. The majority are full-service hospitals (64%), followed by base-service hospitals (20%) and office-based gynecological sites (16%).
About 89% of the sites are certified by the German Cancer Society as (gyneco)oncological centers. Cumulative data for 2022 was provided by 44 sites (35 also took part in last year questioning). On average, the sites treated 24 patients with newly diagnosed OC in 2022 (5-96 patients).
Among the sites, 14% treated fewer than 1 patient per month, 59% treated 1-2 patients per month, and 25% treated more than 2 patients per month. The predominant diagnoses were advanced stage FIGO III or IV(72.0%), serous histology (71.0%), and high-grade carcinoma (72%).
Cyto-reductive surgery was performed in 75.0% of reported cases. Most patients received platinum-based chemotherapy (72%), and if received, 77% responded well.
The result demonstrated that the cumulative data analysis aligns with existing epidemiological data and the ongoing enrollment of a representative cohort of OC patients.
Source:https://www.emma.events/site/programme/?sessiondetail=4534591&trackid=0&a=esgo2023#!
Clinical Trial: https://clinicaltrials.gov/study/NCT04830709
Sehouli J, Arndt T, Pietzner K, Braicu EI, Wimberger P, Link T. Real-World Treatment, Clinical And Patient-Reported Outcomes In Patients With Newly Diagnosed Advanced Ovarian Cancer: Up-Date On The Cumulative Numbers Of Patients Treated At The Sites (NOGGO Ov54, NCT04830709).
